Idelalisib Recruiting Phase 2 Trials for Lymphoma, Large B-Cell, Diffuse (DLBCL) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03576443Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma